Itsa1188, I won't even justify your attack on my crediblity and character with a detailed response. Your attack on me has truly lessened your credibility here as those that know me for a long time through my consistent posts and long term investing approach already know that you do not have honest intentions when you TRY to discredit me.
Identiy_one, why do you fear monger? ".watch, it goes bkrt and the documents they signed with amgen gives amgen the whole beast for the money they laid out..."
Management clearly stated that they were going to be more transparent and to judge them on what they do going forward and that they have the shareholders' interests in mind. I hardly think that bankruptcy is on that agenda as they say they are laser focused on cash utilization.
Sounds like you are just saying "stupid" comments without taking into consideration the facts. Listen to the webcast if you want the facts directly from management.
Teach, you ask "Do we have ANY law that protects retail investors from scammers like these?"
If this scam is so evident, then why are shorts covering and institutions adding shares? Why did the Cayman fund want to convert into shares the minute their bond deal closed? JPM is over 10% invested here and if it is a scam, I am sure there will be a lawsuit recovery. Vanguard, State Street, BlackRock and other large institutions with Research armies on staff have all cleared the way to buy shares here and believe that it is a viable business. I am betting that the only scam here is this absurdly low price that we will be kicking ourselves a year from now that we did not buy enough. But what do I really know? This has been a long and frustrating wait to be sure.
After attending the special meeting, I come out with a renewed sense that the product will be commercialized, it is just a matter of timing. I am not buying any more shares until I see further reports of their progress and I remain cautiously optimistic that we have cleaned house and are heading in the right direction. Things will be more transparent in the weeks to come.
nope, Amgen and Orbimed are partners committed to seeing commercialization of the product. They know the device industry, customers and need for what Unilife has developed.
Teach, I am a real shareholder and I voted for it. Why would I vote against it and end up on an exchange without opportunity for institutional support? This stock is not only lacking support but it is being desecrated by shorts. This move was the only way out in the short term. The longer term will be based on fundamental change and growth (or even a buyout IMO) to get rid of the shorts for good.
Trying to catch up and validate some of your statements Biospeculator:
You stated: ANY selling by Fidelity or The Bakers. Fidelity sold at higher levels FACT.
I couldn't find any current selling by either, where is the source of your fact please.
You stated: The company has shelved IMO 8400 resulting in my immediate exit from this stock, FACT.
Nothing I could find where they are shelving this. Please post source of you fact.
Not sure why the Millennium transactions you highlighted are fearful as they appear to be a fund based on short term trading tactics for quick profit based on their own description:
"We employ a global multi-strategy investment approach, opportunistically engaging in a broad array of trading and investing strategies across a wide group of diversified managers. "
This philosophy does not mean that they do not believe in the long term success prospects of Idera by selling for short term profit. They seem like they move in and out of investments on a regular basis.
The only sharks I know that were circling Unilife were the Whitney Tilson crew and his hedge fund homies. They tried their best to drown the company but let's see if good still triumphs here. I am betting it will. Orbimed and Amgen does not have the gutter reputation that the adversaries have.
Teach, Why do you fear monger ("A scam after another after another. Any charges yet?) after all the positive developments you noted: Amgen, contracts, experienced CFO, annuity business ( with B2B market approach).
You sound like a crooked politician running a deceitful campaign. "LYIN'" Teach
Good point about Amgen's upfront fees. Next quarter may even show a profit it they record it at 100%.
Also, PODD indicates that their R&D is going to increase to $50M per quarter to catch up for not keeping up with the demand and needs for biologic drug delivery. Their technology has to be improved if they want to continue to compete with Unilife
Nothing new to contribute so we wait for Management to execute. If they do so successfully, I expect to have a lot more discussion on growth prospects here.
Macole, Why don't you mention what Hikma did write in the annual report regarding their growth strategy on Page 24:
Just because they don't have an approval YET on a PFS/drug combo doesn't mean that anything is going wrong or they gave up on the idea, but you seem to be wanting to make a point to inject fear to suspect that the FDA had issues without any facts to back it up.
Macole, no need to take my DD as personal to yourself where you have to take a jab at me to wonder what planet I am from. Why do I offend you by sharing what anyone can hear from the Imperium cal? Either you believe what the execs said or you don't. I didn't make it up.
Also, this was a question on that 7/30/15 CC:
Would it help to accelerate market delivery of device if Unilife pursued 510K FDA regulatory process?
This is the answer:
Ian Hanson mentioned it would not work with their partners; Unilife will be taking the lead of partner to maximize the therapy from their point of view
Continued usability studies are underway formatively and with partner as a combination product.
Furthermore, Ramin indicates that there are existing pumps that are do not go through FDA process; so it is their belief that approval is not necessary; they do not think the process is onerous at all.
al28b, it is not clear that FDA approval of a drug/device combo is necessary. It was indicated on the Imperium conference call that it is up to the Pharma company to decide the effective route it wants to take to get their product to market. Ut was noted that there are devices used for drug delivery that do not have FDA approval and that it is not necessary. Obviously, a Big Pharma would want to reassure patients that a device is FDA approved along with its drug, but Unilife made it clear that they would follow their customer's strategy and that it would be THEIR decision to pursue what clinical path it takes it marketing its product.
The problem with Praluent is that Sanofit lost to Amgen on a patent law suit. Obviously, they are going to appeal but Amgen may try to force an injunction in the meantime.